Jacek Kiljański
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jacek Kiljański has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Palash Sharma
Eli Lilly and Company Indianapolis Indiana USA
4 shared publicationsAmelia Torcello-Gómez
Eli Lilly and Company Cork Ireland
3 shared publicationsJoshua A. Levine
Eli Lilly and Company Indianapolis IN USA
3 shared publicationsLuc F. Van Gaal
Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
3 shared publicationsRobert J. Heine
Eli Lilly and Company, Indianapolis, Indiana (R.J.H., E.G.-V., M.Z., E.R., J.K., P.S., A.K., V.T.T.)
3 shared publications- Vivian Thuyanh Thieu
Eli Lilly and Company Indianapolis Indiana USA
3 shared publications
Latest Publications
- 26 May 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (7) , 917-928
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines and clinical practice. To assess the efficacy and safety of tirzepatide versus intensified conventional care (ICC) in participants with early T2D who have inadequate glycemic control with diet, exercise, and metformin. Randomized, open-label, parallel-group, phase 4 trial (SURPASS-EARLY). (ClinicalTrials.gov: NCT05433584). 78 sites in 10 countries. 794 adults with at most 4 years of T2D history treated with metformin. Tirzepatide (15 mg or maximum tolerated dose) or ICC (including GLP-1RAs but excluding tirzepatide) used in clinical practice and supported by local treatment guidelines. The primary objective was to show the noninferiority of tirzepatide to ICC for change in hemoglobin A1c (HbA1c) from baseline to 2 years. Secondary objectives were to show the superiority of tirzepatide for change in HbA1c, weight, and waist circumference. Tirzepatide was superior to ICC for mean changes from baseline to 2 years in HbA1c (-1.99 percentage points [95% CI, -2.12 to -1.87 percentage points] vs. -1.32 percentage points [CI, -1.44 to -1.19 percentage points]; estimated treatment difference [ETD], -0.68 percentage points [CI, -0.84 to -0.51 percentage points]; P < 0.001), weight (ETD, -8.0 kg [CI, -9.39 to -6.50 kg]; P < 0.001), and waist circumference (ETD, -6.2 cm [CI, -7.54 to -4.93 cm]; P < 0.001) (treatment regimen estimand). More participants achieved normoglycemia (HbA1c 1c, weight, and waist circumference, and more participants achieved normoglycemia (HbA1c <5.7%) with tirzepatide than ICC after 2 years. Eli Lilly and Company.
- 26 May 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (7) , 917-928
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
Initiation of treatment with tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1RA), early after a diagnosis of type 2 diabetes (T2D) may establish better and more durable glycemic control than current treatment approaches per guidelines and clinical practice. To assess the efficacy and safety of tirzepatide versus intensified conventional care (ICC) in participants with early T2D who have inadequate glycemic control with diet, exercise, and metformin. Randomized, open-label, parallel-group, phase 4 trial (SURPASS-EARLY). (ClinicalTrials.gov: NCT05433584). 78 sites in 10 countries. 794 adults with at most 4 years of T2D history treated with metformin. Tirzepatide (15 mg or maximum tolerated dose) or ICC (including GLP-1RAs but excluding tirzepatide) used in clinical practice and supported by local treatment guidelines. The primary objective was to show the noninferiority of tirzepatide to ICC for change in hemoglobin A1c (HbA1c) from baseline to 2 years. Secondary objectives were to show the superiority of tirzepatide for change in HbA1c, weight, and waist circumference. Tirzepatide was superior to ICC for mean changes from baseline to 2 years in HbA1c (-1.99 percentage points [95% CI, -2.12 to -1.87 percentage points] vs. -1.32 percentage points [CI, -1.44 to -1.19 percentage points]; estimated treatment difference [ETD], -0.68 percentage points [CI, -0.84 to -0.51 percentage points]; P < 0.001), weight (ETD, -8.0 kg [CI, -9.39 to -6.50 kg]; P < 0.001), and waist circumference (ETD, -6.2 cm [CI, -7.54 to -4.93 cm]; P < 0.001) (treatment regimen estimand). More participants achieved normoglycemia (HbA1c 1c, weight, and waist circumference, and more participants achieved normoglycemia (HbA1c <5.7%) with tirzepatide than ICC after 2 years. Eli Lilly and Company.
- Open Access
- 31 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5498-5505
HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis
Aim: Tirzepatide is a dual glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist for type 2 diabetes, chronic weight management and obstructive sleep apnoea (in the US). To assess the contribution of weight loss (WL) to the observed glycaemic effect, we performed mediation analysis of three randomized, controlled, parallel, 4‐arm SURPASS(S)‐trials; 1, 2 and 5, for a total of 2831 participants. Materials and Methods: WL dependent (WL‐D) and WL independent (WL‐IND) effects on comparator‐adjusted glycated haemoglobin A1c (HbA1c) reduction at Week 40 were estimated using mediation analysis, adjusted for baseline HbA1c and study‐specific stratification factors. Results: The difference in mean HbA1c change from baseline at 40 weeks (total effect) between tirzepatide and the placebo group ranged from −20.0 to −14.6 mmol/mol, and that between tirzepatide and semaglutide (1 mg) ranged from −5.1 to −1.9 mmol/mol. In the placebo‐controlled trials, 12%–27% of the difference in HbA1c change between tirzepatide dose arms and placebo was estimated as being mediated through WL when given as monotherapy (S1), and 25%–45% when on the background of insulin with or without metformin (S5). Compared with semaglutide, 54%–71% of the difference in HbA1c change between tirzepatide and semaglutide was estimated as being WL‐D. Conclusion: The tirzepatide‐induced HbA1c reductions from baseline, compared with placebo or semaglutide, were mediated through both WL‐D and WL‐IND effects. Estimated contributions of WL to the difference in glycaemic efficacy varied and were highest when tirzepatide was compared with semaglutide and less pronounced when compared with placebo. These results help to understand that other factors beyond weight reduction contribute to HbA1c reduction with tirzepatide.
- 31 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5498-5505
Open AccessHbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis
Aim: Tirzepatide is a dual glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist for type 2 diabetes, chronic weight management and obstructive sleep apnoea (in the US). To assess the contribution of weight loss (WL) to the observed glycaemic effect, we performed mediation analysis of three randomized, controlled, parallel, 4‐arm SURPASS(S)‐trials; 1, 2 and 5, for a total of 2831 participants. Materials and Methods: WL dependent (WL‐D) and WL independent (WL‐IND) effects on comparator‐adjusted glycated haemoglobin A1c (HbA1c) reduction at Week 40 were estimated using mediation analysis, adjusted for baseline HbA1c and study‐specific stratification factors. Results: The difference in mean HbA1c change from baseline at 40 weeks (total effect) between tirzepatide and the placebo group ranged from −20.0 to −14.6 mmol/mol, and that between tirzepatide and semaglutide (1 mg) ranged from −5.1 to −1.9 mmol/mol. In the placebo‐controlled trials, 12%–27% of the difference in HbA1c change between tirzepatide dose arms and placebo was estimated as being mediated through WL when given as monotherapy (S1), and 25%–45% when on the background of insulin with or without metformin (S5). Compared with semaglutide, 54%–71% of the difference in HbA1c change between tirzepatide and semaglutide was estimated as being WL‐D. Conclusion: The tirzepatide‐induced HbA1c reductions from baseline, compared with placebo or semaglutide, were mediated through both WL‐D and WL‐IND effects. Estimated contributions of WL to the difference in glycaemic efficacy varied and were highest when tirzepatide was compared with semaglutide and less pronounced when compared with placebo. These results help to understand that other factors beyond weight reduction contribute to HbA1c reduction with tirzepatide.
- 18 March 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (5) , 790-798
Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
OBJECTIVE: To evaluate late (week 40 or 42; hereafter, week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at week 4) or weight response (<5% or ≥5% weight reduction at week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials. RESEARCH DESIGN AND METHODS: This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively. RESULTS: Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline, and a greater percentage were women and White. Early versus nonearly responders in FSG or weight achieved better HbA1c (−2.6% vs. −2.0% or −2.5% vs. −2.2%, respectively) and weight (−11% vs. −10% or −15% vs. −8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile. Nonearly responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild to moderate events) decreased over time and was, in general, comparable between early and nonearly responders. CONCLUSIONS: Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
- 18 March 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (5) , 790-798
Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
OBJECTIVE: To evaluate late (week 40 or 42; hereafter, week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at week 4) or weight response (<5% or ≥5% weight reduction at week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials. RESEARCH DESIGN AND METHODS: This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively. RESULTS: Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline, and a greater percentage were women and White. Early versus nonearly responders in FSG or weight achieved better HbA1c (−2.6% vs. −2.0% or −2.5% vs. −2.2%, respectively) and weight (−11% vs. −10% or −15% vs. −8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile. Nonearly responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild to moderate events) decreased over time and was, in general, comparable between early and nonearly responders. CONCLUSIONS: Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
- Open Access
- 18 March 2025
- Published by American Diabetes Association
Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
Objective To evaluate late (Week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at Week 4) or weight response (<5% or ≥5% weight reduction at Week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials. Research Design and Methods This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to Week 40/42 for efficacy parameters, and gastrointestinal adverse events (GI AEs) were described and analyzed by early response in FSG (SURPASS-1 to -4; N=3,676) or weight (SURPASS-1 to -5; N=4,121) in the efficacy and safety analysis set, respectively. Results Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline and a greater percentage were women and White. Early versus non-early responders in FSG or weight achieved better HbA1c (-2.6% versus -2.0% or -2.5% versus -2.2%) and weight (-11% versus -10% or -15% versus -8%) responses at Week 40/42 and greater improvements in blood pressure and lipids profile. Non-early responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild-to-moderate events) decreased over time and was, in general, comparable between early and non-early responders. Conclusions Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
- 18 March 2025
- Published by American Diabetes Association
Open AccessEarly Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
Objective To evaluate late (Week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at Week 4) or weight response (<5% or ≥5% weight reduction at Week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials. Research Design and Methods This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to Week 40/42 for efficacy parameters, and gastrointestinal adverse events (GI AEs) were described and analyzed by early response in FSG (SURPASS-1 to -4; N=3,676) or weight (SURPASS-1 to -5; N=4,121) in the efficacy and safety analysis set, respectively. Results Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline and a greater percentage were women and White. Early versus non-early responders in FSG or weight achieved better HbA1c (-2.6% versus -2.0% or -2.5% versus -2.2%) and weight (-11% versus -10% or -15% versus -8%) responses at Week 40/42 and greater improvements in blood pressure and lipids profile. Non-early responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild-to-moderate events) decreased over time and was, in general, comparable between early and non-early responders. Conclusions Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
- Open Access
- 18 March 2025
- Published by American Diabetes Association
Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
Objective To evaluate late (Week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at Week 4) or weight response (<5% or ≥5% weight reduction at Week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials. Research Design and Methods This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to Week 40/42 for efficacy parameters, and gastrointestinal adverse events (GI AEs) were described and analyzed by early response in FSG (SURPASS-1 to -4; N=3,676) or weight (SURPASS-1 to -5; N=4,121) in the efficacy and safety analysis set, respectively. Results Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline and a greater percentage were women and White. Early versus non-early responders in FSG or weight achieved better HbA1c (-2.6% versus -2.0% or -2.5% versus -2.2%) and weight (-11% versus -10% or -15% versus -8%) responses at Week 40/42 and greater improvements in blood pressure and lipids profile. Non-early responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild-to-moderate events) decreased over time and was, in general, comparable between early and non-early responders. Conclusions Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
- 18 March 2025
- Published by American Diabetes Association
Open AccessEarly Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
Objective To evaluate late (Week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at Week 4) or weight response (<5% or ≥5% weight reduction at Week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials. Research Design and Methods This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to Week 40/42 for efficacy parameters, and gastrointestinal adverse events (GI AEs) were described and analyzed by early response in FSG (SURPASS-1 to -4; N=3,676) or weight (SURPASS-1 to -5; N=4,121) in the efficacy and safety analysis set, respectively. Results Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline and a greater percentage were women and White. Early versus non-early responders in FSG or weight achieved better HbA1c (-2.6% versus -2.0% or -2.5% versus -2.2%) and weight (-11% versus -10% or -15% versus -8%) responses at Week 40/42 and greater improvements in blood pressure and lipids profile. Non-early responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild-to-moderate events) decreased over time and was, in general, comparable between early and non-early responders. Conclusions Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
- Open Access
- 29 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2553-2560
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme
Aim: To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg). Materials and Methods: HbA1c and body weight data at 40 weeks (SURPASS‐1, ‐2 and ‐5) and 52 weeks (SURPASS‐3 and ‐4) were analysed by trial. Results: Across the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%‐99%, 98%‐99% and 94%‐99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively. Moreover, 87%‐94%, 88%‐95% and 88%‐97% of participants, respectively, experienced weight loss associated with HbA1c reductions. Statistically significant associations (correlation coefficients ranging from 0.1438 to 0.3130 across studies; P ≤ .038) between HbA1c and body weight changes were observed with tirzepatide in SURPASS‐2, ‐3, ‐4 (all doses) and ‐5 (tirzepatide 5 mg only). Conclusions: In this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS‐2, SURPASS‐3 and SURPASS‐4, suggesting that both weight‐independent and weight‐dependent mechanisms are responsible for the tirzepatide‐induced improvement in glycaemic control.
- 29 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2553-2560
Open AccessRelationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme
Aim: To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg). Materials and Methods: HbA1c and body weight data at 40 weeks (SURPASS‐1, ‐2 and ‐5) and 52 weeks (SURPASS‐3 and ‐4) were analysed by trial. Results: Across the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%‐99%, 98%‐99% and 94%‐99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively. Moreover, 87%‐94%, 88%‐95% and 88%‐97% of participants, respectively, experienced weight loss associated with HbA1c reductions. Statistically significant associations (correlation coefficients ranging from 0.1438 to 0.3130 across studies; P ≤ .038) between HbA1c and body weight changes were observed with tirzepatide in SURPASS‐2, ‐3, ‐4 (all doses) and ‐5 (tirzepatide 5 mg only). Conclusions: In this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS‐2, SURPASS‐3 and SURPASS‐4, suggesting that both weight‐independent and weight‐dependent mechanisms are responsible for the tirzepatide‐induced improvement in glycaemic control.
- Open Access
- 10 April 2021
- Published by Springer Nature in Diabetes Therapy
- Vol. 12 (5) , 1463-1474
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Introduction Research has shown that glycemic control is associated with lower rates of microvascular and long-term cardiovascular complications. In the analyses reported here, we examined treatment failure on oral glucose-lowering agents (GLAs), defined as having sustained hemoglobin A1c (HbA1c) ≥ 7%. Methods This study utilized the IBM® MarketScan® Claims and Laboratory Data from 1 January 2012 through 30 June 2018. Adults with type 2 diabetes (T2D) were classified based upon the maximum number of classes of GLAs prescribed per day during the time period from 1 July 2012 through 31 December 2012. Patients were followed for 5.5 years in order to examine time to failure on oral GLAs, defined based upon receipt of ≥ 2 consecutive HbA1c results ≥ 7%. Multivariable analyses employing a Cox proportional hazards model were used to examine time to failure overall and based upon the number of index classes of oral GLAs prescribed. For patients who had sustained HbA1c above the threshold, multivariable analyses examined the duration of time that HbA1c remained above the threshold (i.e, glycemic burden) and whether or not an additional oral or injectable class of GLA was added to the patient treatment regimen (i.e., clinical inertia). Results A total of 4156 patients were included in the study, of whom 16% were identified with sustained HbA1c ≥ 7% after 365 days (1 year) and 36% after 730 days (2 years), with half of all patients having sustained HbA1c above target after 1102 days (3 years). There was a statistically significant difference in time to having sustained HbA1c above target based upon index classes of therapy, with patients treated with more GLAs being quicker to have HbA1c above target (P < 0.0001). Among those patients who were found to have sustained HbA1c ≥ 7%, the average number of days in the post-period that HbA1c remained above target was 1026 (2.8 years). Only 36% of patients with sustained HbA1c above target added a GLA to their treatment regimen and, for patients who did add such a therapy, the average duration from identification of HbA1c above target until treatment intensification was 401 days (1.1 years). Multivariable analyses revealed that, among those with sustained HbA1c ≥ 7%, treatment with more classes of oral GLAs was associated with a significantly higher glycemic burden and significantly lower odds of clinical inertia. Conclusion These results indicate that for many patients treated with oral GLAs, glycemic control is not consistently achieved. For patients with above-target HbA1c , the results indicate a relatively large glycemic burden and clinical inertia towards treatment intensification. The findings illustrate some limitations associated with treatment of T2D with oral GLAs.
- 10 April 2021
- Published by Springer Nature in Diabetes Therapy
- Vol. 12 (5) , 1463-1474
Open AccessTime to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Introduction Research has shown that glycemic control is associated with lower rates of microvascular and long-term cardiovascular complications. In the analyses reported here, we examined treatment failure on oral glucose-lowering agents (GLAs), defined as having sustained hemoglobin A1c (HbA1c) ≥ 7%. Methods This study utilized the IBM® MarketScan® Claims and Laboratory Data from 1 January 2012 through 30 June 2018. Adults with type 2 diabetes (T2D) were classified based upon the maximum number of classes of GLAs prescribed per day during the time period from 1 July 2012 through 31 December 2012. Patients were followed for 5.5 years in order to examine time to failure on oral GLAs, defined based upon receipt of ≥ 2 consecutive HbA1c results ≥ 7%. Multivariable analyses employing a Cox proportional hazards model were used to examine time to failure overall and based upon the number of index classes of oral GLAs prescribed. For patients who had sustained HbA1c above the threshold, multivariable analyses examined the duration of time that HbA1c remained above the threshold (i.e, glycemic burden) and whether or not an additional oral or injectable class of GLA was added to the patient treatment regimen (i.e., clinical inertia). Results A total of 4156 patients were included in the study, of whom 16% were identified with sustained HbA1c ≥ 7% after 365 days (1 year) and 36% after 730 days (2 years), with half of all patients having sustained HbA1c above target after 1102 days (3 years). There was a statistically significant difference in time to having sustained HbA1c above target based upon index classes of therapy, with patients treated with more GLAs being quicker to have HbA1c above target (P < 0.0001). Among those patients who were found to have sustained HbA1c ≥ 7%, the average number of days in the post-period that HbA1c remained above target was 1026 (2.8 years). Only 36% of patients with sustained HbA1c above target added a GLA to their treatment regimen and, for patients who did add such a therapy, the average duration from identification of HbA1c above target until treatment intensification was 401 days (1.1 years). Multivariable analyses revealed that, among those with sustained HbA1c ≥ 7%, treatment with more classes of oral GLAs was associated with a significantly higher glycemic burden and significantly lower odds of clinical inertia. Conclusion These results indicate that for many patients treated with oral GLAs, glycemic control is not consistently achieved. For patients with above-target HbA1c , the results indicate a relatively large glycemic burden and clinical inertia towards treatment intensification. The findings illustrate some limitations associated with treatment of T2D with oral GLAs.
- Open Access
- 26 February 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (8) , 1231-1242
Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial
Understanding the benefits and risks of treatments to be used by older individuals (≥65 years old) is critical for informed therapeutic decisions. Glucose‐lowering therapy for older patients with diabetes should be tailored to suit their clinical condition, comorbidities and impaired functional status, including varying degrees of frailty. However, despite the rapidly growing population of older adults with diabetes, there are few dedicated clinical trials evaluating glucose‐lowering treatment in older people. Conducting clinical trials in the older population poses multiple significant challenges. Despite the general agreement that individualizing treatment goals and avoiding hypoglycaemia is paramount for the therapy of older people with diabetes, there are conflicting perspectives on specific glycaemic targets that should be adopted and on use of specific drugs and treatment strategies. Assessment of functional status, frailty and comorbidities is not routinely performed in diabetes trials, contributing to insufficient characterization of older study participants. Moreover, significant operational barriers and problems make successful enrolment and completion of such studies difficult. In this review paper, we summarize the current guidelines and literature on conducting such trials, as well as the learnings from our own clinical trial (IMPERIUM) that assessed different glucose‐lowering strategies in older people with type 2 diabetes. We discuss the importance of strategies to improve study design, enrolment and attrition. Apart from summarizing some practical advice to facilitate the successful conduct of studies, we highlight key gaps and needs that warrant further research.
- 26 February 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (8) , 1231-1242
Open AccessEvaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial
Understanding the benefits and risks of treatments to be used by older individuals (≥65 years old) is critical for informed therapeutic decisions. Glucose‐lowering therapy for older patients with diabetes should be tailored to suit their clinical condition, comorbidities and impaired functional status, including varying degrees of frailty. However, despite the rapidly growing population of older adults with diabetes, there are few dedicated clinical trials evaluating glucose‐lowering treatment in older people. Conducting clinical trials in the older population poses multiple significant challenges. Despite the general agreement that individualizing treatment goals and avoiding hypoglycaemia is paramount for the therapy of older people with diabetes, there are conflicting perspectives on specific glycaemic targets that should be adopted and on use of specific drugs and treatment strategies. Assessment of functional status, frailty and comorbidities is not routinely performed in diabetes trials, contributing to insufficient characterization of older study participants. Moreover, significant operational barriers and problems make successful enrolment and completion of such studies difficult. In this review paper, we summarize the current guidelines and literature on conducting such trials, as well as the learnings from our own clinical trial (IMPERIUM) that assessed different glucose‐lowering strategies in older people with type 2 diabetes. We discuss the importance of strategies to improve study design, enrolment and attrition. Apart from summarizing some practical advice to facilitate the successful conduct of studies, we highlight key gaps and needs that warrant further research.
- Open Access
- 24 April 2019
- Published by Springer Nature in Diabetes Therapy
- Vol. 10 (3) , 805-833
Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
Insulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical trials and postmarketing studies. We also provide recommendations and opinions on the optimal use of IGlar-100 in this population. The findings from the studies highlighted in our review indicate that IGlar-100 can be a suitable treatment option for East Asians with T2DM, from initial therapy in combination with oral antihyperglycemic medications through to different combinations and intensification models.
- 24 April 2019
- Published by Springer Nature in Diabetes Therapy
- Vol. 10 (3) , 805-833
Open AccessUse of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
Insulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical trials and postmarketing studies. We also provide recommendations and opinions on the optimal use of IGlar-100 in this population. The findings from the studies highlighted in our review indicate that IGlar-100 can be a suitable treatment option for East Asians with T2DM, from initial therapy in combination with oral antihyperglycemic medications through to different combinations and intensification models.
- Open Access
- 8 August 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (1) , 148-156
Glycaemic outcomes of an I ndividualized treat M ent a P proach for old ER vulnerable pat I ents: A randomized, controlled st U dy in type 2 diabetes M ellitus ( IMPERIUM )
Aims: To compare the glycaemic outcomes of 2 glucose‐lowering treatment strategies in vulnerable (moderately ill and/or frail) patients aged ≥65 years with type 2 diabetes whose individual HbA1c targets were not met with diet/exercise and/or oral anti‐hyperglycaemic medications ( OAM s). Methods: The primary endpoint of this study was a composite of achieving/maintaining individualized HbA1c targets without “clinically significant” hypoglycaemia (severe hypoglycaemia or repeated hypoglycaemia causing interruption of patients’ activities or blood glucose n = 99) with a non‐sulphonylurea OAM and a glucagon‐like peptide‐1 receptor agonist as the first injectable. Strategy‐ B comprised non‐glucose‐dependent therapies ( n = 93) with sulphonylurea as the preferred OAM and insulin glargine as the first injectable. Results: There was no significant difference between Strategy‐ A and Strategy‐ B in percentages of patients achieving the primary endpoint (64.5% vs 54.9%; P = .190). Mean incidences ( A vs B ) of total (10.2% vs 53.8%), documented symptomatic (5.1% vs 36.6%), and asymptomatic (8.2% vs 32.3%) hypoglycaemia were lower for Strategy‐ A ( P < .001 each). Proportions of patients achieving/maintaining HbA1c target ( A , 63.3% vs B , 55.9%) were similar. Conclusion: Similar proportions of older, vulnerable aged ≥65 years patients with type 2 diabetes achieved/maintained glycaemic treatment goals without clinically significant hypoglycaemia with Strategies A or B. However, Strategy‐A resulted in lower risk of total, documented symptomatic, and asymptomatic hypoglycaemia. These results identify an approach of potential clinical benefit in this age group and will inform future clinical research in older patients with type 2 diabetes.
- 8 August 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (1) , 148-156
Open AccessGlycaemic outcomes of an I ndividualized treat M ent a P proach for old ER vulnerable pat I ents: A randomized, controlled st U dy in type 2 diabetes M ellitus ( IMPERIUM )
Aims: To compare the glycaemic outcomes of 2 glucose‐lowering treatment strategies in vulnerable (moderately ill and/or frail) patients aged ≥65 years with type 2 diabetes whose individual HbA1c targets were not met with diet/exercise and/or oral anti‐hyperglycaemic medications ( OAM s). Methods: The primary endpoint of this study was a composite of achieving/maintaining individualized HbA1c targets without “clinically significant” hypoglycaemia (severe hypoglycaemia or repeated hypoglycaemia causing interruption of patients’ activities or blood glucose n = 99) with a non‐sulphonylurea OAM and a glucagon‐like peptide‐1 receptor agonist as the first injectable. Strategy‐ B comprised non‐glucose‐dependent therapies ( n = 93) with sulphonylurea as the preferred OAM and insulin glargine as the first injectable. Results: There was no significant difference between Strategy‐ A and Strategy‐ B in percentages of patients achieving the primary endpoint (64.5% vs 54.9%; P = .190). Mean incidences ( A vs B ) of total (10.2% vs 53.8%), documented symptomatic (5.1% vs 36.6%), and asymptomatic (8.2% vs 32.3%) hypoglycaemia were lower for Strategy‐ A ( P < .001 each). Proportions of patients achieving/maintaining HbA1c target ( A , 63.3% vs B , 55.9%) were similar. Conclusion: Similar proportions of older, vulnerable aged ≥65 years patients with type 2 diabetes achieved/maintained glycaemic treatment goals without clinically significant hypoglycaemia with Strategies A or B. However, Strategy‐A resulted in lower risk of total, documented symptomatic, and asymptomatic hypoglycaemia. These results identify an approach of potential clinical benefit in this age group and will inform future clinical research in older patients with type 2 diabetes.